Public Health Emergency - Leading a Nation Prepared
Protecting the Americans from influenza pandemic is a daunting challenge. The National Influenza Vaccine Modernization Strategy 2020-2030 is aimed at building domestic capacity and capability through the use of new technologies to speed up the overall process of influenza vaccine manufacturing as well as other complementary medical countermeasures.
HHS has secured more than 500,000 treatment courses of remdesivir by Gilead Sciences through September, the first authorized therapeutic for the treatment of COVID-19. The drug will be allocated by HHS to state health departments for purchase by American hospitals.
ICUs across the world are finding that sepsis, a medical emergency, can occur among patients with COVID-19. BARDA is working with its partners on solving sepsis together with cutting-edge diagnostic solutions.
FDA revoked the EUA that allowed for the drugs donated to the SNS to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was not available, or participation in a clinical trial was not feasible. The agency determined that the legal criteria for issuing an EUA are no longer met.
Check out the new National Influenza Vaccine Modernization Strategy to learn how the federal government plans to support the next generation of influenza vaccines with technology and approaches that can be leveraged in other infectious disease outbreaks.
